Vijaya Diagnostic Centre Q1 FY27 Earnings Call Transcript Released
Vijaya Diagnostic Centre reported Q1 FY27 revenue growth of 22.8% to ₹231 crore, with PAT up 37.6% to ₹53 crore. EBITDA rose 34% to ₹98 crore, with margins at 42.7%. The company commissioned new hubs and spokes, including advanced imaging in Bengaluru. Capex for expansion is estimated at ₹190-195 crore, including land acquisition in AP.
The announcement details significant revenue growth, improved profitability, and aggressive expansion plans, including new advanced facilities and strategic investments, which are material for investors and the company's future trajectory.
The company reported strong year-on-year growth in revenue, PAT, and EBITDA, along with expansion plans and improved margins, indicating a positive financial performance and outlook.
Vijaya Diagnostic Centre Limited has released the transcript of its Earnings Conference Call held on August 07, 2026. The call, which followed the declaration of un-audited financial results for the quarter ended June 30, 2026, featured insights from Ms. Suprita Reddy (Managing Director and CEO), Mr. Narasimha Raju (Chief Financial Officer), and Mr. Dhiren Gala (Head, Investor Relations and Corporate Development).
During the call, the management highlighted a strong year-on-year revenue growth of approximately 22.8% for Q1 FY27, driven by a volume growth of nearly 16.5%. Profit After Tax (PAT) saw a growth of 37.6% to ₹53 crores, with a healthy PAT margin of 23%. EBITDA grew by 34% year-on-year to ₹98 crores, resulting in an improved EBITDA margin of 42.7%.
The company announced the addition of one hub centre in Gachibowli, Hyderabad, equipped with a 160-slice cardiac CT, and the commissioning of four spoke centres across Hyderabad, AP, and Pune. Notably, a flagship hub in Bengaluru's JP Nagar was commissioned, featuring advanced imaging technologies like a digital PET-CT with an inbuilt cardiac CT and a 75-centimeter wide-bore 3T Omega MR. The company also plans to commission another 9 hub centres and 10 to 12 spoke centres, along with a state-of-the-art Panjagutta reference laboratory. Additionally, an investment of ₹8 crores to ₹10 crores is planned for acquiring land in Andhra Pradesh to set up a new hub centre, contributing to an overall estimated capex of ₹190 crores to ₹195 crores for the expansion.
Management expressed confidence in maintaining EBITDA margins above 40%, citing operating leverage from existing clusters and the scalability of pathology revenues. The company also noted a strong performance in its B2C model, with B2C revenue contributing 92% and a growing wellness segment contributing 14.8% of revenues. The company continues to focus on expanding its network and strengthening its leadership team to ensure sustainable growth.
What to do with a filing like this
Vijaya Diagnostic Centre Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Vijaya Diagnostic Centre Limited. Read the original for the full detail.